Investigation of a possible pharmacokinetic interaction between roflumilast and salbutamol in healthy male subjects

Study identifier:BY217/FHP014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Sex

Male

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Nov 1998

Primary Completion Date: -

Study Completion Date: 01 Mar 1999

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Collaborators

Inclusion and exclusion criteria

Location

Research Facility

Germany

Arms	Assigned Interventions

"There is no result for the study"

Documents available

BY217-FHP014-RDS-2014-10-26.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com